OLOncology Letters1792-10741792-1082D.A. Spandidos10.3892/ol.2018.9853OL-0-0-9853ArticlesAssociations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancerMiyoshiYuichiro1ShienTadahiko1OgiyaAkiko2IshidaNaoko3YamazakiKieko2HoriiRie4HorimotoYoshiya5MasudaNorikazu6YasojimaHiroyuki6InaoTouko7OsakoTomofumi811TakahashiMasato9TomiokaNobumoto9Wanifuchi-EndoYumi10HosodaMitsuchika3DoiharaHiroyoshi1YamashitaHiroko3Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama 700-8558, JapanDepartment of Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Breast Surgery, Hokkaido University Hospital, Hokkaido 060-8648, JapanDivision of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, JapanDepartment of Breast Oncology, Juntendo University School of Medicine, Tokyo 113-8431, JapanDepartment of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka 540-0006, JapanDepartment of Breast and Endocrine Surgery, Graduate School of Medical Science Kumamoto University, Kumamoto 860-8556, JapanDepartment of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto 862-8505, JapanDepartment of Breast Surgery, NHO Hokkaido Cancer Center, Hokkaido 003-0804, JapanDepartment of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, JapanCorrespondence to: Dr Tadahiko Shien, Department of Breast and Endocrinological Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan, E-mail: tshien@md.okayama-u.ac.jp
11Present address: Department of Breast Surgery, Kumamoto Shinto General Hospital, Kumamoto 862-8655, Japan
The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total of 184 cases with early distant recurrence detected within 5 years following the primary operation, 134 with late distant recurrence diagnosed following 5 years or longer and 321 controls without recurrence for >10 years following starting the initial treatment for ER-positive/HER2 negative breast cancer, registered in 9 institutions, were analyzed. The distributions of TILs and their clinical relevance were investigated. TIL distributions did not differ significantly among the early, late and no recurrence groups, employing a 30% cut-off point as a dichotomous variable. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30% cut-off point (P=0.064). The TIL distributions were significantly associated with nodal metastasis (P=0.004), ER status (P=0.045), progesterone receptor (PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 labeling index (LI) (P=0.002) in the no recurrence group and with the Ki67 LI in the recurrence groups (P=0.002 in early recurrence group, P=0.023 in late recurrence group). High TIL distributions also predicted shorter survival time following the detection of recurrence (P=0.026). However, these prognostic interactions were not significant in multivariate analysis (P=0.200). The present retrospective study demonstrated no significant interaction between TIL proportions and the timing of recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes, which tended to be more responsive to chemotherapy. The clinical relevance of stromal TILs for identifying patients who would likely benefit from additional therapies merits further investigation in a larger patient population.
breast cancerestrogen receptor positivehuman epidermal growth factor receptor type 2 negativetumor infiltrating lymphocytesprognosisIntroduction
Breast cancer is a heterogeneous disease, which is categorized into subtypes according to gene expressions and clinicopathological features (1,2). Luminal subtype, which is one of the recognized subtypes, is characteristically estrogen receptor (ER) positive and human epidermal growth factor receptor type 2 (HER2) negative. Endocrine therapy is considered first, and then chemotherapy in high-risk groups, based on the pathological diagnosis which includes histological classification, tumor grade, the Ki67 labeling index (LI) and lymph node metastasis, as adjuvant systemic therapies (3,4). However, some luminal tumors recur regardless of adjuvant therapy, which is a critical problem that must be overcome to improve patient survival (5).
The importance of tumor infiltrating lymphocytes (TILs) has increasingly been recognized in recent years (6–9). The host immune system appears to influence the development of breast carcinoma (10). In addition to these observations, chemotherapy might trigger recruitment of lymphocytes to tumor nests (11,12). We also need to understand whether TILs have an important role in patients receiving endocrine therapy (13,14). Therefore, we need to understand the biological features and functions of TILs in the breast cancer microenvironment. Many studies have compared TILs among breast cancers to determine their prognostic value. Abundant TILs in highly proliferative tumors such as triple negative breast cancer and HER2 positive breast cancer have been demonstrated (15,16). In a recent study, marked TIL infiltration was found to be associated with better outcomes for patients with these subtypes (17–23). On the other hand, recruitment of TILs was also reported to have variable impacts on the outcomes of ER positive/HER2 negative breast cancers (13,15,24–28). However, details of TIL distributions are lacking as there have been few studies focusing on the timing of recurrence. In addition, the relationships between TIL distributions and the efficacies of systemic therapies such as chemotherapy and endocrine therapy remain poorly understood.
We retrospectively collected data from ER positive/HER2 negative breast cancer cases with early and late distant recurrence and from patients who remained recurrence free for more than ten years, and then identified clinicopathological factors predicting early and late recurrence in ER-positive/HER2 negative breast cancer cases (29–31). We next investigated the biological and prognostic significance of TILs, by comparing these three groups. We compared proportions of TILs among these groups and investigated associations between TIL distributions and clinicopathological factors in each group.
Materials and methodsCases and clinical samples
This retrospective multi-institution study was conducted as Scientific Research of the Japanese Breast Cancer Society (29,30). We registered 223 consecutive patients with early distant recurrence and 149 consecutive patients with late distant recurrence of ER-positive/HER2 negative breast cancer, who had undergone breast surgery and/or neoadjuvant chemotherapy between January 2000 and December 2004, from nine institutions. These institutes were Okayama University, the Cancer Institute Hospital, the Japanese Foundation for Cancer Research, Hokkaido University, Juntendo University, National Health Organization (NHO) Osaka National Hospital, Kumamoto University, Kumamoto City Hospital, the NHO Hokkaido Cancer Center, and Nagoya City University. Early recurrence was diagnosed based on distant metastasis within 5 years, late recurrence as distant metastasis more than 5 years after initial treatment. For each late recurrence patient, in general, two age-matched patients free of recurrence for more than ten years were randomly selected using RAND in combination with Excel software at each institution. In total, 321 patients who had been recurrence free for more than ten years served as study controls. The study protocol was approved by the institutional review board (IRB) of each participating institution and conformed to the guidelines of the 1996 Declaration of Helsinki. Opting out and a waiver of informed consent were options, as anonymized archival specimens were used in this retrospective study.
Expressions of ER, PgR, HER2, and Ki67 LI were centrally assessed employing immunohistochemistry. HER2-positive tumors were excluded from this study. The details were documented in our previous report (30).
Hematoxylin and eosin (H&E) stained sections were available from 639 of the registered patients (early recurrence: n=184, late recurrence: n=134, no recurrence: n=321). In these cases with available sections, TIL proportions were compared among the three groups. We also assessed the relationships between TIL proportions and other clinicopathological features. Moreover, the relationship between TIL proportions and survival time after recurrence was evaluated for both groups with recurrent disease, i.e., both late and early recurrence.
Evaluation of TILs
H&E-stained sections were utilized for evaluation of TILs. The percentages of stromal lymphocytes, serving as a predefined criterion in Denkert's et al and Loi's et al reports (8,25,32), were evaluated by two observers. Stromal TILs were measured as the percentage of immune cells in stromal tissue within the tumor that showed a mononuclear immunological infiltrate (Fig. 1). Heterogeneous distributions were documented in almost all of the sections examined. Therefore, hot spots, cold spots, and Tertiary Lymphoid Structure were not taken into consideration in any of the measurements conducted; instead, one representative area was selected and evaluated. The findings were categorized according to three possible cut-off points for TIL proportions (10, 30, and 50%).
Statistical analysis
Differences in clinicopathological data were compared between cases with and without recurrence employing the Chi-square test. The Chi square test was utilized when investigating associations between the TIL distribution and clinicopathological features in each group. The Kaplan-Meier method was used to estimate survival duration from the time-point of recurrence detection. Differences between overall survival curves were determined with the log-rank test. For both univariate and multivariate analyses, Cox regression was used to evaluate the influences of the variables on survival time. All of the data were analyzed employing JMP 11.0.0 (SAS Institute Inc., Cary, NC, USA) statistical software. A value of P<0.05 was considered to indicate a statistically significant difference.
ResultsPatient characteristics
Patient characteristics are presented in Table I. The median follow-up durations were 72 (range, 14–179), 133 (range, 67–177) and 128 (range, 57–179) months in the early, late and no recurrence groups, respectively. During follow-up of these 639 patients, 69.5% (128/184) of those with early recurrence and 31.3% (42/134) of those with late recurrence died of breast cancer. The histology was invasive ductal carcinoma in 94.0% (173/184), 93.2% (125/134) and 93.1% (299/321) of the early, late, and no recurrence groups, respectively. The recurrences were local in 20.1% (37/184) of the early recurrence group and in 28.3% (38/134) of the late recurrence group. Adjuvant endocrine therapy alone had been administered to 28.8% (53/184) of the early recurrence cases, 41.0% (55/134) of the late recurrence cases, and 56.0% (180/321) of the controls, while 53.8% (99/184), 51.4% (69/134) and 32.3% (104/321), respectively, received both adjuvant chemotherapy and endocrine therapy. The adjuvant chemotherapy consisted mainly of anthracyclines and/or taxanes.
Distributions of TILs
The TIL distributions are shown in Table II. Percentages of TILs did not differ significantly among the three groups (P=0.556). In previous reports, various cut-off points were utilized (10, 35, 50 and 60%) (14,25,27,28,33). However, there are as yet no standardized cut-off points. We selected a 30% cut-off point from among the potential values because there were few cases with TIL proportions lower than 10% or more than 50% in our study. We thus conducted the following analyses employing 30% as the cut-off point.
In each case, various adjuvant therapies had been administered. Therefore, we investigated the TIL distributions according to the presence of adjuvant chemotherapy and endocrine therapy. The odds ratios for recurrence with high TILs are presented in Table III. There were no significant interactions between TIL proportions and the time of recurrence in any of the subgroups. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30% cut-off point (P=0.064).
Associations of TIL proportions with clinicopathological factors
We assessed whether the proportion of TILs was associated with clinicopathological factors (Table IV). TILs in breast cancer specimens correlated significantly with the Ki67 LI (P=0.002) in the early recurrence group. Nodal metastasis (P=0.008), tumor grade (P=0.008), and Ki67 LI (P=0.023) showed significant associations with the proportion of TILs in the late recurrence group. Nodal metastasis (P=0.004), ER status (P=0.045), PgR status (P=0.002), tumor grade (P=0.021), and Ki67 LI (P=0.002) showed significant associations with the proportion of TILs in the no recurrence group.
Survival time after distant recurrence
We analyzed 318 cases (early recurrence: 184 (58%), late recurrence: 134 (42%)) to compare survival duration from the time of recurrence detection between the cases with high and low TIL proportions (Fig. 2). The median follow-up duration from the detection of recurrence until death due to breast cancer was 39 (0–141) months in the early recurrence and 34 (0–89) months in the late recurrence group. The Kaplan-Meier method revealed a significant difference between these two groups in TIL distributions (P=0.026) (Fig. 2). Moreover, the Kaplan-Meier method revealed a trend for higher TIL proportions in the early recurrence group (P=0.080), while there was no difference in the late recurrence group (P=0.187). Univariate analysis of all cases with recurrence revealed TILs, nodal metastasis, and tumor grade to be significant prognostic factors. We selected significant parameters (P<0.20) from among various conventional confounding factors, and performed a multivariate analysis in which nodal metastasis, PgR, tumor grade, and Ki67 LI served as categorical variables. In this multivariate analysis, lymph node metastasis (P=0.027) was found to be an independent prognostic factor, while the proportion of TILs was not (P=0.200) (Table V).
Discussion
In this retrospective study, the TIL proportions did not vary among recurrence patterns. However, among those receiving chemotherapy and endocrine therapy, cases with higher TIL proportions tended to have fewer recurrences, though the difference did not reach statistical significance. In ER positive breast cancer, the significance of TILs for predicting recurrence appears to be minor, but those cases showing TIL recruitment might benefit from chemotherapy. Higher proportions of TILs were also observed in cancers showing markedly proliferative phenotypes. Further study is needed to identify associations among lymphocyte recruitment, aggressive features of the tumor and responsiveness to chemotherapy.
Many researchers have focused on the significance of differences in TIL proportions among breast cancer cases (7,34). Methods for TIL evaluation varied among these studies. The methods used ranged from evaluation of H&E sections for lymphocyte density and area, immune cell typing with immunohistochemistry and immune cell related transcriptome techniques (35–43). Many previous studies showed higher proportions of TILs to be observed in such de-differentiated tumors as triple negative breast cancer (25,33,44). As to pathological examinations, tumor grade and Ki67 LI both correlated with higher TIL proportions (25). However, in those with triple negative breast cancer, higher TIL proportions also indicated a better prognosis according to several reports (44,45), while one study found that in ER positive breast cancer accompanied by less recruitment of TILs than the triple negative subtype, the TIL proportions lacked prognostic significance (46). On the other hand, according to a few studies, TILs also correlated with the outcomes of patients with ER positive breast tumors (14,33). The conflicting results obtained in these studies may reflect different study populations and evaluation methods. We utilized H&E-stained sections to evaluate representative densities of lymphocytes in the stromal area. The data obtained in this case control study of luminal breast tumors were analyzed by comparing TIL proportions among recurrence patterns. We also evaluated time of recurrence in a long-term follow-up study.
In our full study population, TILs showed no correlation with the timing of recurrence. However, among those receiving chemotherapy and endocrine therapy, cases with higher TIL proportions tended to experience fewer recurrences, though the difference did not reach statistical significance. We speculated that patients with breast tumors showing higher TIL proportions might benefit more from chemotherapy. ER positive breast cancer patients received endocrine therapy, which was an important aspect of clinical management. Different adjuvant therapy modalities might make interpreting the roles of TILs difficult. Denkert et al (32) defined lymphocyte predominant breast cancer (LPBC) as showing evenly and widely distributed tumor lymphocytes in tumor nests (16). LPBC was defined as a mean density of TILs of at least 50%. However, most luminal breast cancers showed heterogeneous and low-density infiltration of lymphocytes into the stromal area. Therefore, identifying LPBC might not allow adequate evaluation of luminal breast tumors (16). Reliable methods for evaluating these heterogeneous distributions and the low density of TILs are as yet lacking. According to Vassiliki's report, investigation employing a 35% cut-off point as a binary parameter revealed an interaction between high TIL proportions and better outcomes, but this interaction was not statistically significant (33). According to Denkert's et al report, a high proportion of TILs is associated with a high pathological complete response rate (27). Jang and Kwon, employing a 10% cut-off value, reported high TIL proportions to be associated with better outcomes for luminal B (ER positive, HER2 negative, and higher Ki67) breast cancer patients who received adjuvant anthracycline (28). Higher TIL recruitment might make cancer cells more responsive to chemotherapy. The various cut-off points need to be investigated in terms of their significance when applied with various chemotherapy regimens. Studies utilizing ecological measurements and immune cell typing with immunohistochemistry have shown associations of lymphocytes, specifically their functions, with patient outcomes (15,35,47–49). The value of H&E-stained sections for determining lymphocyte density and area might be limited because the function of lymphocyte recruitment around tumor nests is not revealed by this method. Lymphocytes might promote or negatively regulate the growth of tumor nests. Flow cytometry, immunohistochemistry, and transcriptome analysis may be useful for determining the cell counts of specific lymphocyte populations. Further detailed studies, focusing on the function, extent and localization of tumor lymphocytes, are needed.
According to previous reports, high TIL proportions were found in aggressive breast cancer subtypes (15,25). In our present study, in each group, TILs were identified in specimens from cases with a high Ki67 LI. Moreover, the TIL distribution correlated significantly with nodal metastasis, ER status, PgR status, tumor grade, and Ki67 LI in the no recurrence group. High TIL proportions correlated with rapid tumor growth, leading to death from breast cancer recurrence. Studies have demonstrated associations between high TIL proportions and poorer outcomes (13,26,27). On the other hand, several reports have noted an association between TIL proportions and the effects of chemotherapy (15). We speculated that infiltration and accumulation of TILs might reflect both the aggressiveness and the fragility of cancer cells, suggesting that patients would benefit from cytotoxic agents. However, minor clusters of TILs in luminal breast tumors appear to have little, if any, role in recurrence and thus might not be important when considering various adjuvant settings. On the other hand, patients with breast tumors showing TIL recruitment might have a slightly poorer prognosis after recurrence due to the aggressive nature of these tumors. Luminal subtype tumors are characteristically ER positive and HER2 negative, reflecting heterogeneous breast cancer biology. Hormonal treatment is considered first, and then chemotherapy in high-risk groups, based on the pathological diagnosis which includes histological classification, tumor grade, Ki67 LI and lymph node metastasis. Therefore, we need to investigate the significance of TILs as a predictive factor for selecting therapies such as chemotherapy, endocrine therapy and molecular targeted therapy among prospective cohorts in a well-planned adjuvant setting. TILs may serve as a surrogate marker for systemic therapies. Additional translational research is also required to fully investigate the significance of potential TIL biomarkers.
Our study is limited by its retrospective, case control design. Therapy selections and intervals varied among physicians. Our results might thus have been affected by selection bias. Also, our sample was small. Therefore, our conclusions are inevitably somewhat controversial. Verification of our findings requires a prospective, well-planned study with a large cohort. In the present study, we utilized a predefined cut-off point to categorize the subgroups according to different TIL proportions. This cut-off point was selected from among potential cut-off value candidates based on our dataset. Therefore, this cut-off point might not be optimal. An optimal cut-off point needs to be established, in a future study, based on the details of TIL proportions as a continuous parameter.
In our present study, recruitment of TILs was more often observed in aggressive phenotypes, such as ER positive, HER2 negative breast cancer, but did not significantly predict recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes which tended to be more responsive to chemotherapy. The significance of stromal TILs for identifying patients likely to benefit from additional therapies merits investigation in a large future study.
Acknowledgements
The authors would like to thank for Dr Bierta Barfod (Department of Neurosurgery, Katsuta Hospital, Ibaraki, Japan) for proofreading the manuscript.
Funding
The present study was supported by a Grant-in-Aid for Scientific Research from the Japanese Breast Cancer Society and the Health and Labour Sciences Research Expenses for Commission, Applied Research for Innovative Treatment of Cancer, H26-applied-general-043 from the Ministry of Health, Labour and Welfare and the Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development, AMED (grant no. 17ck0106307h0001).
Availability of data and materials
The datasets used during the present study are available from the corresponding author upon reasonable request.
Authors' contributions
TS, AO, RH, YH, NM, TI, TO, MT, YWE and HYam designed the study. YM, TS, AO, NI, KY, RH, YH, NM, HYas, TI, TO, MT, NT, YWE, MH, HD, and HYam collected and assessed patient data. NI, MH, and HYam performed the immunohistochemical studies and evaluated the stained specimens. YM and TS evaluated TIL proportions in H&E-stained sections. YM, HD and TS analyzed the patient data. YM, TS and HD drafted the manuscript. AO, NO, KY, RH, YH, NM, HYas, TI, TO, MT, NT, YWE, MH and HYam revised the manuscript. All authors read and approved the manuscript for submission.
Ethics approval and consent to participate
The study protocol was approved by the IRB of each participating institution. Patients were given the choice of opting out and an informed consent waiver was an option as anonymized archival specimens were used in this retrospective study.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
AbbreviationsTILs
tumor infiltrating lymphocytes
ER
estrogen receptor
PgR
progesterone receptor
HER2
human epidermal growth factor receptor 2
Ki67 LI
Ki67 labeling index
IRB
institutional review board
HE
hematoxylin-eosin
OR
odds ratio
CI
confidence interval
IDC-NST
invasive ductal carcinoma of no special type
A+T
anthracycline and taxane
A
anthracycline
T
taxane
CMF
cyclophosphamide, methotrexate and fluorouracil
TAM
tamoxifen
TAM+LHRH
tamoxifen and luteinizing hormone-releasing hormone
TAM→AI
tamoxifen followed by aromatase inhibitor
TAM+LHRH→AI
tamoxifen and luteinizing hormone-releasing hormone followed by aromatase inhibitor
AI
aromatase inhibitor
LHRH
luteinizing hormone-releasing hormone
EarR
early recurrence
LateR
late recurrence
NoR
no recurrence
LPBC
lymphocyte-predominant breast cancer
CT
chemotherapy
ET
endocrine therapy
CT+ET
chemotherapy + endocrine therapy
ReferencesMaoXYLeeMJZhuJZhuCLawSMSnijdersAMGenome-wide screen identifies a novel prognostic signature for breast cancer survivalOncotarget81400314016201728122328TsaiMLoSAudehWQamarRBudwayRLevineEWhitworthPMavromatisBZonROldhamDAssociation of 70-gene signature assay findings with physicians' treatment guidance for patients with early breast cancer classified as intermediate risk by the 21-gene assayJAMA Oncol4e173470201810.1001/jamaoncol.2017.347029075751PalmieriCJonesAThe 2011 EBCTCG polychemotherapy overviewLancet379390392201210.1016/S0140-6736(11)61823-022152852SinghKHeXKalifeETEhdaivandSWangYSungCJRelationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx resultsBreast Cancer Res Treat1682934201810.1007/s10549-017-4619-429230662RouzierRPerouCMSymmansWFIbrahimNCristofanilliMAndersonKHessKRStecJAyersMWagnerPBreast cancer molecular subtypes respond differently to preoperative chemotherapyClin Cancer Res1156785685200510.1158/1078-0432.CCR-04-242116115903SalgadoRDenkertCDemariaSSirtaineNKlauschenFPruneriGWienertSVan den EyndenGBaehnerFLPenault-LlorcaFThe evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014Ann Oncol26259271201510.1093/annonc/mdu45025214542DenkertCvon MinckwitzGBraseJCSinnBVGadeSKronenwettRPfitznerBMSalatCLoiSSchmittWDTumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersJ Clin Oncol33983991201510.1200/JCO.2014.58.196725534375DenkertCWienertSPoterieALoiblSBudcziesJBadveSBago-HorvathZBaneABedriSBrockJStandardized evaluation of tumor-infiltrating lymphocytes in breast cancer: Results of the ring studies of the international immuno-oncology biomarker working groupMod Pathol2911551164201610.1038/modpathol.2016.10927363491DieciMVRadosevic-RobinNFinebergSvan den EyndenGTernesNPenault-LlorcaFPruneriGD'AlfonsoTMDemariaSCastanedaCUpdate on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the international immuno-oncology biomarker working group on breast cancerSemin Cancer Biol521625201810.1016/j.semcancer.2017.10.00329024776HorimotoYHayashiTArakawaAPathology of healing: What else might we look at?Cancer Med535863587201610.1002/cam4.95227781408DieciMVArnedosMDelalogeSAndreFQuantification of residual risk of relapse in breast cancer patients optimally treatedBreast22Suppl 2S92S95201310.1016/j.breast.2013.07.01724074801DemariaSVolmMDShapiroRLYeeHTOratzRFormentiSCMuggiaFSymmansWFDevelopment of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapyClin Cancer Res730253030200111595690BlokEJEngelsCCDekker-EnsinkGMeershoek-Klein KranenbargEPutterHSmitVTHBMLiefersGJMordenJPBlissJMCoombesRCExploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancerBreast Cancer Res TreatMay152018(Epub ahead of print)10.1007/s10549-018-4785-zDieciMVFrassoldatiAGeneraliDBisagniGPiacentiniFCavannaLCagossiKPuglisiFMichelottiABerardiRTumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: Results from two prospective trialsBreast Cancer Res Treat163295302201710.1007/s10549-017-4191-y28289852DenkertCvon MinckwitzGDarb-EsfahaniSLedererBHeppnerBIWeberKEBudcziesJHuoberJKlauschenFFurlanettoJTumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapyLancet Oncol194050201810.1016/S1470-2045(17)30904-X29233559OhtaniHMori-ShiraishiKNakajimaMUekiHDefining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosisPathol Int65644651201510.1111/pin.1235526530981SalgadoRDenkertCCampbellCSavasPNuciforoPAuraCde AzambujaEEidtmannHEllisCEBaselgaJTumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO trialJAMA Oncol1448454201510.1001/jamaoncol.2015.083026181252TsoutsouPGBourhisJCoukosGTumor-infiltrating lymphocytes in triple-negative breast cancer: A biomarker for use beyond prognosis?J Clin Oncol3312971298201510.1200/JCO.2014.59.280825753438Garcia-TeijidoPCabalMLFernándezIPPérezYFTumor-infiltrating lymphocytes in triple negative breast cancer: The future of immune targetingClin Med Insights Oncol10Suppl 13139201627081325PruneriGGrayKPVingianiAVialeGCuriglianoGCriscitielloCLángIRuhstallerTGianniLGoldhirschATumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22–00Breast Cancer Res Treat158323331201610.1007/s10549-016-3863-327372069Ingold HeppnerBUntchMDenkertCPfitznerBMLedererBSchmittWEidtmannHFaschingPATeschHSolbachCTumor-infiltrating lymphocytes: A predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancerClin Cancer Res2257475754201610.1158/1078-0432.CCR-15-233827189162AdamsSGrayRJDemariaSGoldsteinLPerezEAShulmanLNMartinoSWangMJonesVESaphnerTJPrognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199J Clin Oncol3229592966201410.1200/JCO.2013.55.049125071121LoiSMichielsSSalgadoRSirtaineNJoseVFumagalliDKellokumpu-LehtinenPLBonoPKatajaVDesmedtCTumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trialAnn Oncol2515441550201410.1093/annonc/mdu11224608200HidaAISagaraYYotsumotoDKanemitsuSKawanoJBabaSRaiYOshiroYAogiKSagaraYOhiYPrognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapiesBreast Cancer Res Treat15819201610.1007/s10549-016-3848-227260189LoiSSirtaineNPietteFSalgadoRVialeGVan EenooFRouasGFrancisPCrownJPHitreEPrognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98J Clin Oncol31860867201310.1200/JCO.2011.41.090223341518ChungYRKimHJJangMHParkSYPrognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor statusBreast Cancer Res Treat161409420201710.1007/s10549-016-4072-927913931DenkertCvon MinckwitzGDarb-EsfahaniSLedererBHeppnerBIWeberKEBudcziesJHuoberJKlauschenFFurlanettoJTumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapyLancet Oncol194050201810.1016/S1470-2045(17)30904-X29233559JangNKwonHJParkMHKangSHBaeYKPrognostic value of tumor-infiltrating lymphocyte density assessed using a standardized method based on molecular subtypes and adjuvant chemotherapy in invasive breast cancerAnn Surg Oncol25937946201810.1245/s10434-017-6332-229330719OgiyaAYamazakiKHoriiRShienTHorimotoYMasudaNInaoTHosodaMIshidaNOsakoTPost-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancerBreast Cancer24473482201710.1007/s12282-016-0730-327628678YamashitaHOgiyaAShienTHorimotoYMasudaNInaoTOsakoTTakahashiMEndoYHosodaMClinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancerBreast Cancer23830843201610.1007/s12282-015-0649-026467036MiyoshiYShienTOgiyaAIshidaNYamazakiKHoriiRHorimotoYMasudaNYasojimaHInaoTDifferences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrenceBreast Cancer Res1873201610.1186/s13058-016-0731-327368476DenkertCLoiblSNoskeARollerMMüllerBMKomorMBudcziesJDarb-EsfahaniSKronenwettRHanuschCTumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancerJ Clin Oncol28105113201010.1200/JCO.2009.23.737019917869KotoulaVChatzopoulosKLakisSAlexopoulouZTimotheadouEZagouriFPentheroudakisGGogasHGalaniEEfstratiouITumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: A pooled analysis of four prospective adjuvant trialsOncotarget750745087201610.18632/oncotarget.623126506242DieciMVCriscitielloCGoubarAVialeGContePGuarneriVFicarraGMathieuMCDelalogeSCuriglianoGAndreFPrognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter studyAnn Oncol25611618201410.1093/annonc/mdt55624401929WatanabeTHidaAIInoueNImamuraMFujimotoYAkazawaKHirotaSMiyoshiYAbundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancersBreast Cancer Res Treat168135145201810.1007/s10549-017-4575-z29168063WangKShenTSiegalGPWeiSThe CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancerHum Pathol69110117201710.1016/j.humpath.2017.09.01228993275TuMMRahimMMASayedCMahmoudABMakrigiannisAPImmunosurveillance and immunoediting of breast cancer via Class I MHC receptorsCancer Immunol Res510161028201710.1158/2326-6066.CIR-17-005628924054TsangJYAuWLLoKYNiYBHlaingTHuJChanSKChanKFCheungSYTseGMPD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patientsBreast Cancer Res Treat1621930201710.1007/s10549-016-4095-228058578StovgaardESNielsenDHogdallEBalslevETriple negative breast cancer-prognostic role of immune-related factors: A systematic reviewActa Oncol577482201810.1080/0284186X.2017.140018029168430NguyenLTosunABFineJLLeeAVTaylorDLChennubhotlaSCSpatial statistics for segmenting histological structures in H&E stained tissue imagesIEEE Trans Med Imaging3615221532201710.1109/TMI.2017.268151928328502SemeraroMAdamJStollGLouvetEChabaKPoirier-ColameVSauvatASenovillaLVacchelliEBloyNThe ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situOncoimmunology5e1218106201610.1080/2162402X.2016.121810627853639BottiGCollinaFScognamiglioGRaoFPelusoVDe CecioRPiezzoMLandiGDe LaurentiisMCantileMDi BonitoMProgrammed death ligand 1 (PD-L1) tumor expression is associated with a better prognosis and diabetic disease in triple negative breast cancer patientsInt J Mol Sci18piiE459201710.3390/ijms1802045928230773KochiMIwamotoTNiikuraNBianchiniGMasudaSMizooTNogamiTShienTMotokiTTairaNTumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancerBreast Cancer Res Treat1673947201810.1007/s10549-017-4502-328905250KotoulaVLakisSVlachosISGiannoulatouEZagouriFAlexopoulouZGogasHPectasidesDAravantinosGEfstratiouITumor infiltrating lymphocytes affect the outcome of patients with operable triple-negative breast cancer in combination with mutated amino acid classesPLoS One11e0163138201610.1371/journal.pone.016313827685159CastanedaCAMittendorfECasavilcaSWuYCastilloMArboledaPNunezTGuerraHBarrionuevoCDolores-CernaKTumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapyWorld J Clin Oncol7387394201610.5306/wjco.v7.i5.38727777881LoiSTumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacyOncoimmunology2e24720201310.4161/onci.2472024073365MaleyCCKoelbleKNatrajanRAktipisAYuanYAn ecological measure of immune-cancer colocalization as a prognostic factor for breast cancerBreast Cancer Res17131201510.1186/s13058-015-0638-426395345QianFQingpingYLinquanWXiaojinHRongshouWShanshanRWenjunLYongHEnliangLHigh tumor-infiltrating FoxP3+ T cells predict poor survival in estrogen receptor-positive breast cancer: A meta-analysisEur J Surg Oncol4312581264201710.1016/j.ejso.2017.01.01128214052KlauschenFMüllerKRBinderABockmayrMHägeleMSeegererPWienertSPruneriGde MariaSBadveSScoring of tumor-infiltrating lymphocytes: From visual estimation to machine learningSemin Cancer Biol52151157201810.1016/j.semcancer.2018.07.00129990622
Hematoxylin and eosin staining of TILs in breast tumor cells. Among stromal areas within tumor nests, a small number of TILs ranging from 10 to 29% were identified in (A), but in (B) TIL proportions exceeded 50% (magnification, ×400). TILs, tumor infiltrating lymphocytes.
Survival time from recurrence detection until mortality due to breast cancer. There were significant differences in the (A) recurrence group as a whole. However, there was no significant difference in the (B) early recurrence group or in the (C) late recurrence group. TILs, tumor infiltrating lymphocytes.
Clinicopathological factors according to the time of recurrence.
Number (%)
P-value
Variable
EarR (n=184)
LateR (n=134)
NoR (n=321)
EarR vs. NoR
LateR vs. NoR
EarR vs. LateR
Age (years)
≤50
82 (44.5)
49 (36.5)
120 (37.3)
0.113
0.869
0.151
>50
102 (55.4)
85 (63.4)
201 (62.6)
Menopausal status
Post-
90 (48.9)
81 (60.4)
171 (53.2)
0.345
0.159
0.041a
Pre-
94 (51.0)
53 (39.5)
150 (46.7)
Bilateral breast cancer
Absent
169 (91.8)
121 (90.3)
319 (99.3)
<0.001c
<0.001c
0.631
Present
15 (8.1)
13 (9.7)
2 (0.6)
cT (mm)
≤20
49 (26.6)
44 (32.8)
187 (58.2)
<0.001c
<0.001c
0.23
>20
135 (73.3)
90 (67.1)
134 (41.7)
cN
Negative
93 (50.5)
79 (58.9)
267 (83.1)
<0.001c
<0.001c
0.136
Positive
91 (49.4)
55 (41.0)
54 (16.8)
Histological type
IDC-NST
171 (92.9)
124 (92.5)
297 (92.5)
0.864
0.995
0.892
Others
13 (7.0)
10 (7.4)
24 (7.4)
Estrogen receptor (%)
<10
16 (8.7)
10 (7.4)
27 (8.4)
0.396
0.367
0.915
10–50
57 (30.9)
43 (32.0)
82 (25.5)
≥50
111 (60.3)
81 (60.4)
212 (66.0)
Progesterone receptor (%)
≤20%
85 (46.2)
59 (44.0)
133 (41.4)
0.298
0.609
0.701
>20%
99 (53.8)
75 (55.9)
188 (58.5)
Tumor grade
1 or 2
131 (71.2)
106 (79.1)
278 (86.6)
<0.001c
<0.001c
0.107
3
53 (28.8)
28 (20.9)
43 (13.4)
Ki 67(%)
≤20
136 (73.9)
114 (85.0)
265 (82.5)
<0.001c
0.507
0.014a
>20
48 (26.0)
20 (14.9)
56 (17.4)
Local recurrence
Absent
136 (78.6)
96 (71.6)
0
Present
37 (21.3)
38 (28.3)
0
Surgical treatment
Total mastectomy
117 (63.5)
78 (58.2)
106 (33.0)
0.076
<0.001c
0.331
Partial mastectomy
67 (36.4)
56 (41.7)
215 (66.9)
Radiation therapy
Absent
100 (54.3)
92 (68.6)
149 (46.4)
<0.001c
<0.001c
0.009b
Present
84 (45.6)
42 (31.3)
172 (53.5)
Adjuvant treatment
none
13 (7.0)
4 (2.9)
30 (9.3)
<0.001c
<0.001c
0.021a
chemotherapy only
19 (10.3)
6 (4.4)
7 (2.1)
endocrine therapy only
53 (28.8)
55 (41.0)
180 (56.0)
combined therapy
99 (53.8)
69 (51.4)
104 (32.4)
Neoadjuvant chemotherapy
Absent
168 (91.3)
131 (97.7)
305 (95.3)
0.076
0.198
0.011a
Present
16 (8.7)
3 (2.2)
15 (4.6)
Chemotherapy
A+T
54 (29.3)
22 (16.4)
42 (13.0)
A
39 (21.2)
31 (23.1)
40 (12.4)
T
6 (3.2)
7 (5.2)
13 (4.0)
CMF
17 (9.2)
12 (8.9)
13 (4.0)
Others
2 (1.0)
3 (2.2)
3 (0.9)
None
66 (35.8)
59 (44.0)
210 (65.4)
Endocrine therapy
TAM
61 (33.1)
34 (25.3)
68 (21.1)
TAM+LHRH
30 (16.3)
18 (13.4)
35 (10.9)
TAM→AI
16 (8.7)
36 (26.8)
72 (22.4)
TAM+LHRH→AI
1 (0.5)
3 (2.2)
15 (4.6)
AI
39 (21.2)
27 (20.1)
87 (27.1)
LHRH
5 (2.7)
6 (4.4)
7 (2.1)
None
32 (17.3)
10 (7.4)
37 (11.5)
P<0.05
P<0.01
P<0.001. EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; IDC-NST, invasive ductal carcinoma of no special type; A+T, anthracycline and taxane; A, anthracycline; T, taxane; CMF, cyclophosphamide, methotrexate, and fluorouracil; TAM, tamoxifen; TAM+LHRH, tamoxifen and luteinizing hormone-releasing hormone; TAM→AI, tamoxifen followed by aromatase inhibitor; TAM+LHRH→AI, tamoxifen and luteinizing hormone-releasing hormone followed by aromatase inhibitor; AI, aromatase inhibitor; LHRH, luteinizing hormone-releasing hormone; Ki67 Labeling index, Ki67 LI.
Differences in the distributions of TIL proportions among recurrence pattern.
Number (%)
TIL positivity
EarR
LateR
NoR
P-value
0-10%
11 (5.9)
4 (2.9)
17 (5.3)
0.556
10-30%
151 (82.0)
113 (84.3)
261 (81.3)
30-50%
19 (10.3)
15 (11.1)
31 (9.6)
50-100%
3 (1.6)
2 (1.4)
12 (3.7)
EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; TILs, tumor infiltrating lymphocytes.
Odds ratios between recurrence patterns.
Number with high TILs/total number
EarR vs. NoR
LateR vs. NoR
EarR vs. LateR
Adjuvant therapy
EarR
LateR
NoR
OR (CI) P-value
OR (CI) P-value
OR (CI) P-value
All
22/184
17/134
43/321
0.877 (0.499–1.505)
0.939 (0.502–1.686)
0.934 (0.476–1.859)
P=0.64
P=0.838
P=0.844
CT+ET
13/99
12/69
24/104
0.503 (0.234–1.041)
0.701 (0.315–1.494)
0.718 (0.304–1.703)
P=0.064
P=0.363
P=0.447
ET
5/53
4/55
15/180
1.145 (0.358–3.129)
0.862 (0.237–2.502)
1.328 (0.332–5.641)
P=0.803
P=0.862
P=0.684
EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; OR, odds Ratio; CI, confidence interval; CT, chemotherapy; ET, endocrine therapy; CT+ET, chemotherapy + endocrine therapy; TILs, tumor infiltrating lymphocytes.
Proportions of high and low TIL numbers in EarR, LateR, and NoR cases, in association with clinicopathological factors.
Number of TILs (%)
EarR
LateR
NoR
Variable
High
Low
P-value
High
Low
P-value
High
Low
P-value
TILs
≤50
12 (54.5)
70 (43.2)
0.317
3 (17.6)
46 (39.3)
0.068
16 (37.2)
104 (37.4)
0.979
>50
10 (45.4)
92 (56.7)
14 (82.3)
71 (60.6)
27 (62.7)
174 (62.5)
Tumor size (mm)
≤20
6 (27.2)
43 (26.5)
0.942
4 (23.5)
40 (34.1)
0.369
24 (55.8)
163 (58.6)
0.727
>20
16 (72.7)
119 (73.4)
13 (76.4)
77 (65.8)
19 (44.1)
115 (41.3)
Lymph node metastases
Negative
11 (50.0)
82 (50.6)
0.956
5 (29.4)
74 (63.2)
0.008b
29 (67.4)
238 (85.6)
0.004
Positive
11 (50.0)
80 (49.3)
12 (70.5)
43 (36.7)
14 (32.5)
40 (14.3)
Estrogen receptor (%)
<10
1 (4.5)
15 (9.2)
0.622
1 (5.8)
9 (7.6)
0.917
8 (18.60)
19 (6.8)
0.045a
10–50
6 (27.2)
51 (31.4)
5 (29.4)
38 (32.4)
12 (27.91)
70 (25.1)
≥50
15 (68.1)
96 (59.2)
11 (64.7)
70 (59.8)
23 (53.49)
189 (67.9)
Progesterone receptor (%)
≤20%
9 (40.9)
76 (46.9)
0.594
9 (52.9)
50 (42.7)
0.430
27 (62.7)
106 (38.1)
0.002b
>20%
13 (59.0)
86 (53.0)
8 (47.0)
67 (57.2)
16 (37.2)
172 (61.8)
Histological grade
1 or 2
13 (59.0)
118 (72.8)
0.194
9 (52.9)
97 (82.9)
0.008b
32 (74.4)
246 (88.4)
0.020a
3
9 (40.9)
44 (27.1)
8 (47.0)
20 (17.0)
11 (25.5)
32 (11.5)
Ki 67 (%)
≤20
10 (45.4)
126 (77.7)
0.002b
11 (64.7)
103 (88.0)
0.023a
28 (65.1)
237 (85.2)
0.002b
>20
12 (54.5)
36 (22.2)
6 (35.2)
14 (11.9)
15 (34.8)
41 (14.7)
P<0.05
P<0.01. EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; Ki67, Ki67 Labeling index; TILs, tumor infiltrating lymphocytes.
Univariate and multivariate analyses for survival time from recurrence detection until mortality due to breast cancer.